

EP 00003389704 A1

Anmeldeland: EP
Anmeldenummer: 16822409
Anmeldedatum: 15.12.2016
Veröffentlichungsdatum: 24.10.2018
Priorität: EP 15307004 15.12.2015
Priorität: EP 2016081157 15.12.2016
Hauptklasse: A61K 39/02(2006.01,A)
Nebeklasse: C07K 16/12(2006.01,A)
MCD-Hauptklasse: A61K 39/02(2006.01,A)
MCD-Nebeklasse: C07K 16/12(2006.01,A)
CPC: A61K 39/0216(2013.01)
CPC: A61K 39/114(2013.01)
CPC: A61K 2039/51(2013.01)
CPC: A61K 2039/521(2013.01)
CPC: A61K 2039/522(2013.01)
CPC: A61P 3/04(2018.01)
CPC: A61P 3/10(2018.01)
CPC: A61P 9/12(2018.01)
CPC: A61P 31/00(2018.01)
Erfinder: BLASCO-BAQUE VINCENT, FR
Erfinder: BURCELIN RÉMY, FR
Erfinder: GARIDOU LUCILE, FR
Anmelder: CT HOSPITALIER UNIVERSITAIRE TOULOUSE, FR
Anmelder: INST NAT SANTE RECH MED, FR
Anmelder: UNIV TOULOUSE 3 PAUL SABATIER, FR

DWPI 2010 © Thomson Reuters. All rights reserved.

AN_WPI: 201742266R

TI_WPI: Use of composition as vaccine or isolated antibody having specificity for Porphyromonas gingivalis for preventing or treating periodontitis, diabetes, obesity or complications e.g. hepatic and respiratory complications in mammal

AB_WPI: NOVELTY: Use of composition as a vaccine or isolated antibody having specificity for Porphyromonas gingivalis is claimed for preventing or treating periodontitis, diabetes, obesity and/or their complications in a subject. The composition comprises at least one active agent chosen from attenuated P.gingivalis, inactivated P.gingivalis, subunit of P.gingivalis, recombinant or isolated immunogenic polypeptide or peptide from P.gingivalis or cDNA from P.gingivalis.

ACTIVITY: Antiinflammatory; Antidiabetic; Anorectic; Hypotensive; Cardiovascular-Gen.; Hepatotropic.

MECHANISM OF ACTION: Vaccine. Test details are described but no results given.

USE: The composition or isolated antibody having specificity for P.gingivalis is useful for preventing or treating periodontitis, diabetes, obesity and/or their complications, and reducing the effect of comorbidity, preferably periodontitis on worsening of diabetes and/or obesity in a subject. The complication is chosen from cardiometabolic complications, hepatic complications, respiratory complications, renal complications, nervous system complications and inflammation complications (all claimed). The metabolic complications of obesity are e.g. insulin resistance and hyperinsulinemia. The cardiovascular complications are e.g. hypertension, and cardiovascular disease. The hepatic complications are e.g. hepatic steatosis, and non-alcoholic steatohepatitis. The subject is mammal.

ADVANTAGE: The composition does not include any adjuvant.

PHARMACEUTICALS: Preferred Composition: The composition further comprises (a) at least one additional active agent chosen from live attenuated Fusobacterium nucleatum, killed or inactivated F.nucleatum, subunit of F.nucleatum, recombinant or isolated immunogenic polypeptide or peptide from F.nucleatum or a cDNA from F.nucleatum, and/or (b) at least one additional active agent chosen from live attenuated Prevotella intermedia, killed or inactivated P.intermedia, subunit of P.intermedia, recombinant or isolated immunogenic polypeptide or peptide from P.intermedia or cDNA from P.intermedia. The composition is administered in gum or tooth of subject. Preferred Agent: The active agent is attenuated or inactivated P.gingivalis. The antibody is used in combination with at least one isolated antibody having specificity for Fusobacterium nucleatum and/or Prevotella intermedia. Preferred Subject: The subject (a) is at risk of metabolic disease, (b) from overweight, hypertension and/or high fasting blood glucose, (c) is under high fat diet, (d) suffers from periodontitis, or (e) suffers from diabetes, in particular type 2 diabetes, and/or obesity.

The composition or isolated antibody is administered by topical, oral, parenteral, intranasal, intravenous, intramuscular, subcutaneous or intraocular route.

EXAMPLE: No suitable example given.

IW_WPI: COMPOSITION VACCINE ISOLATE ANTIBODY SPECIFIC PREVENT TREAT PERIODONTAL DIABETES OBESITY COMPLICATED HEPATO RESPIRATION MAMMAL

DC_WPI: B04, D16

MC_WPI: B04F10A, B04G07, B04N03J, B14C03, B14D01E, B14E12, B14F01, B14F02, B14F10, B14N06B, B14N10, B14N12, B14S04, B14S11D1, B14S11D2, D05H07

[DE]IMPFUNG GEGEN DIABETES, ADIPOSITAS UND DAMIT VERBUNDENEN KOMPLIKATIONEN

[EN]VACCINATION AGAINST DIABETES, OBESITY AND COMPLICATIONS THEREOF

[FR]VACCINATION CONTRE LE DIABÈTE, L'OBÉSITÉ ET LEURS COMPLICATIONS